<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547036</url>
  </required_header>
  <id_info>
    <org_study_id>0010152018</org_study_id>
    <nct_id>NCT04547036</nct_id>
  </id_info>
  <brief_title>Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation</brief_title>
  <official_title>Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paracelsus Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paracelsus Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the change of endothelial cell count after XEN45&#xD;
      in patients with or without cataract operation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE Corneal endothelial cell loss is a known sequela of glaucoma tube shunt&#xD;
      implantation. Big tube shunts show a decrease of endothelial cell count postoperatively&#xD;
      (-11.5% after Ahmed glaucoma valves and -12.4% after Molteno shunt 2 years postoperatively).&#xD;
      The objective of this study is to evaluate the change of endothelial cell count after XEN45&#xD;
      in patients with or without cataract operation.&#xD;
&#xD;
      PATIENT POPULATION In 140 open angle eyes central endothelial cell counts were recorded&#xD;
      preoperatively, before the XEN45 implantation was performed in Dept. Ophthalmology at&#xD;
      Paracelsus Medical University Salzburg. XEN45s were already performed in the year 2013-2017&#xD;
      (so up to 5 years) in open angle glaucoma eyes in combination with or without cataract&#xD;
      operation. In these eyes central endothelial cell count and central corneal thickness was&#xD;
      measured preoperatively and documented in patients records.&#xD;
&#xD;
      STUDY DESIGN A prospective, observational, monocentric trial to evaluate the course of&#xD;
      endothelial cell density after the XEN implant. The study will take place in the Dept.&#xD;
      Ophthalmology at Paracelsus Medical University Salzburg/SALK.&#xD;
&#xD;
      Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be&#xD;
      summoned to a consecutive endothelial cell count record and measurement of central corneal&#xD;
      thickness postoperatively. Informed consents will be obtained from patients, who are&#xD;
      interested in participating in the study.&#xD;
&#xD;
      Patients will be assessed for endothelial cell density and the position of the XEN45 measured&#xD;
      by anterior segment optical coherence tomography. The distance of the XEN45 to cornea, the&#xD;
      angle of the tube, and the tube length in the anterior chamber will be recorded with anterior&#xD;
      segment optical coherence tomography. Endothelial cell density will be measured on 3&#xD;
      positions: central, superior-nasal (location of XEN45 implantation), infero-temporal (far&#xD;
      away for the XEN45 implant).&#xD;
&#xD;
      OUTCOME PARAMETERS The primary endpoint is the change of central endothelial cell density&#xD;
      compared to preoperative data.&#xD;
&#xD;
      Secondary objectives are the differences of supero-nasal and infero-temporal endothelial cell&#xD;
      density compared to the central endothelial cell density, and pachymetry compared to&#xD;
      preoperative data.&#xD;
&#xD;
      EXAMINATION SCHEDULE Subjects will undergo study visits at the following times: preoperative&#xD;
      data (2013-2017) out of patient records, postoperative visit in the year 2018-2020 (1-7 years&#xD;
      post XEN45 implantation).&#xD;
&#xD;
      CLINICAL PARAMETERS&#xD;
&#xD;
      The following clinical assessments will be performed at the postoperative examination:&#xD;
&#xD;
        1. Endothelial cell count on different locations of the study eye&#xD;
&#xD;
        2. Central corneal thickness&#xD;
&#xD;
        3. Anterior segment optical coherence tomography (to determine the position of the XEN45)&#xD;
&#xD;
        4. Slit lamp examination of the cornea, anterior segment including gonioscopy (to determine&#xD;
           the position of the XEN45), and dilated fundus examination&#xD;
&#xD;
        5. Best corrected visual acuity&#xD;
&#xD;
        6. Measurement of IOP&#xD;
&#xD;
        7. Number and frequency of ocular (glaucoma) medications&#xD;
&#xD;
        8. Ocular symptoms and assessment of complications (especially symptoms, which may be a&#xD;
           hint for loss of endothelial cell count)&#xD;
&#xD;
        9. Secondary surgical procedures (if applicable including needlings, lasers, cataract&#xD;
           operation, bleb revisions, keratoplasty, secondary IOP lowering procedures, other&#xD;
           operations)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Cell Count Change</measure>
    <time_frame>baseline compared to 1-5 years postoperative</time_frame>
    <description>The primary endpoint is the change of central endothelial cell density compared to preoperative data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">129</enrollment>
  <condition>Glaucoma</condition>
  <condition>Endothelial Cell Loss, Corneal</condition>
  <arm_group>
    <arm_group_label>Endothelial cell count measurment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN45</intervention_name>
    <description>Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.</description>
    <arm_group_label>Endothelial cell count measurment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be&#xD;
        summoned to a consecutive endothelial cell count record and measurement of central corneal&#xD;
        thickness postoperatively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Open Angle Glaucoma&#xD;
&#xD;
          2. History past XEN45 implantation with or without combined cataract procedure&#xD;
&#xD;
          3. Available preoperative endothelial cell count data not older than 1 year before XEN&#xD;
             operation without any operation between the day of data record and XEN45 operation.&#xD;
&#xD;
          4. Age 18 years or older and of legal age of consent&#xD;
&#xD;
          5. Signed written informed consent&#xD;
&#xD;
          6. Availability, willingness, and sufficient cognitive awareness to comply with&#xD;
             examination procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients with secondary IOP lowering procedures (excluding SLT, needlings, bleb&#xD;
        revisions, YAG lasers, Argon lasers) after XEN implantation will be excluded from analysis,&#xD;
        because the secondary IOP lowering procedures may influence endothelial cell count itself.&#xD;
        Cataract operations without complications are no exclusion criteria, but have to be&#xD;
        recorded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. Ophthalmology and Optometry Paracelsus Medical University</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>July 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Paracelsus Medical University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Herbert Reitsamer</investigator_full_name>
    <investigator_title>Prof. Dr. Herbert Reitsamer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Corneal Endothelial Cell Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04547036/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>XEN45 Implantation With and Without Combined Cataract Surgery</title>
          <description>Patients with history past XEN45 implantation with and without combined cataract surgery and preoperatively recorded baseline central endothelial cell counts were included for the postoperative examination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eyes</population>
      <group_list>
        <group group_id="B1">
          <title>XEN45 Implantation With and Without Combined Cataract Surgery</title>
          <description>Eyes with a history past XEN45 implantation with and without combined cataract surgery and preoperatively recorded baseline central endothelial cell counts were included for the postoperative examination.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Cell Count Change</title>
        <description>The primary endpoint is the change of central endothelial cell density compared to preoperative data.</description>
        <time_frame>baseline compared to 1-5 years postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endothelial Cell Count Measurment</title>
            <description>XEN45: Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Cell Count Change</title>
          <description>The primary endpoint is the change of central endothelial cell density compared to preoperative data.</description>
          <units>% change compared to baseline</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-3" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-7" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-7" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3.7 (range 1.6-6.7) years</time_frame>
      <desc>The investigators classified the adverse events based on the following definitions according to ISO 14155 (2011).&#xD;
Adverse Event (AE) Adverse Device Effect (ADE) Device deficiency Serious Adverse Event (SAE) Serious Adverse Device Effect (SADE)</desc>
      <group_list>
        <group group_id="E1">
          <title>XEN45 Implantation With and Without Combined Cataract Surgery</title>
          <description>Patients with history past XEN45 implantation with and without combined cataract surgery and preoperatively recorded baseline central endothelial cell counts were included for the postoperative examination</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <description>Minimum one small spot</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>conreal guttae</sub_title>
                <description>all eyes had pre-existing corneal guttae at baseline visit</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Conjuncitval emema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cystoid macular edema</sub_title>
                <description>underlying causes were partially pre-existing at baseline visit</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Conjuncitval hemorhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Epiretinal membrane</sub_title>
                <description>partially pre-existing at baseline.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>PD Dr. Markus Lenzhofer PhD FEBO</name_or_title>
      <organization>Dept. Ophthalmology at Paracelsus Medical University Salzburg</organization>
      <phone>+43 57255 ext 24201</phone>
      <email>m.lenzhofer@salk.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

